Xvivo Perfusion Management

Management Kriterienprüfungen 3/4

Xvivo Perfusion CEO ist Christoffer Rosenblad , ernannt in Jan 2022, hat eine Amtszeit von 2.83 Jahren. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von SEK25.11M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 4.1 Jahre.

Wichtige Informationen

Christoffer Rosenblad

Geschäftsführender

SEK 5.0m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.8yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.1yrs

Jüngste Management Updates

Recent updates

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 04

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 27

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Oct 25

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Geschäftsführer

Christoffer Rosenblad (49 yo)

2.8yrs

Amtszeit

SEK 5,031,000

Vergütung

Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Christoffer Rosenblad	Chief Executive Officer	2.8yrs	SEK 5.03m	0.18% SEK 25.1m
Kristoffer Nordstrom	Chief Financial Officer	4yrs	keine Daten	0.0085% SEK 1.2m
Lena Hagman	COO & Deputy CEO	1.9yrs	keine Daten	0.0063% SEK 903.1k
Johan Holmstrom	Senior Vice President of Commercial EMEA	less than a year	keine Daten	0.012% SEK 1.7m
Ylva Vihoj	Global Human Resources Director	1.8yrs	keine Daten	keine Daten
Magnus Nilsson	Senior Advisor	4.4yrs	SEK 1.62m	keine Daten
Andreas Wallinder	Chief Medical Officer	4.2yrs	keine Daten	0.011% SEK 1.5m
Mark Reade	Senior Vice President of North America	less than a year	keine Daten	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrenes Management: XVIVODas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Gosta Johannesson	Chairman of the Board	11.8yrs	SEK 440.00k	0.015% SEK 2.1m
Lars Henriksson	Independent Director	4.1yrs	keine Daten	0.0076% SEK 1.1m
Erik Stromqvist	Independent Director	1.6yrs	keine Daten	0.18% SEK 25.5m
Camilla Oberg	Independent Director	8.5yrs	SEK 130.00k	0.0034% SEK 486.4k
Lena Hoglund	Independent Director	4.1yrs	keine Daten	0.0041% SEK 587.4k
Goran Dellgren	Independent Director	2.6yrs	keine Daten	keine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

63.5yo

Durchschnittliches Alter

Erfahrener Vorstand: XVIVODie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).

Xvivo Perfusion Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Independent Director recently bought kr346k worth of stock

Xvivo Perfusion AB (publ) Appoints Lena Hagman as Deputy Chief Executive Officer

Independent Director recently bought kr222k worth of stock

Chairman of the Board recently bought kr281k worth of stock

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Recent updates

Consensus EPS estimates fall by 11%, revenue upgraded

Independent Director recently bought kr346k worth of stock

Xvivo Perfusion AB (publ) Appoints Lena Hagman as Deputy Chief Executive Officer

Consensus EPS estimates fall by 13%, revenue upgraded

Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News

Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts

New major risk - Earnings quality

With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%